We previously showed that cetuximab downregulates HIF-1α in cancer cells sensitive to anti-EGFR therapy through inhibition of HIF-1α protein synthesis, which was prevented by expression of a myristoylated Akt that is constitutively active [16]. The gene discussed is AKT1; the disease is cancer.